DOCSLIB.ORG

Amoxicillin and Clavulanate Potassium Powder, for Suspension

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Amoxicillin and Clavulanate Potassium Powder, for Suspension AUGMENTIN ES-600- amoxicillin and clavulanate potassium powder, for suspension Dr Reddys Laboratories Inc ---------- AUGMENTIN ES-600® Powder for Oral Suspension (amoxicillin/clavulanate potassium) 1111 PRESCRIBING INFORMATION To reduce the development of drug-resistant bacteria and maintain the effectiveness of AUGMENTIN ES-600 Powder for Oral Suspension and other antibacterial drugs, AUGMENTIN ES-600 Powder for Oral Suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION AUGMENTIN ES-600 Powder for Oral Suspension is an oral antibacterial combination consisting of the semisynthetic antibiotic amoxicillin and the β-lactamase inhibitor, clavulanate potassium (the potassium salt of clavulanic acid). Amoxicillin is an analog of ampicillin, derived from the basic penicillin nucleus, 6-aminopenicillanic acid. The amoxicillin molecular formula is C16H19N3O5S•3H2O, and the molecular weight is 419.46. Chemically, amoxicillin is (2S,5R,6R)-6- [(R)-(-)-2-Amino-2-(p-hydroxyphenyl)acetamido]-3,3-dimethyl-7-oxo-4-thia-1- azabicyclo[3.2.0]heptane-2-carboxylic acid trihydrate and may be represented structurally as: Clavulanic acid is produced by the fermentation of Streptomyces clavuligerus. It is a β-lactam structurally related to the penicillins and possesses the ability to inactivate a wide variety of β-lactamases by blocking the active sites of these enzymes. Clavulanic acid is particularly active against the clinically important plasmid-mediated β-lactamases frequently responsible for transferred drug resistance to penicillins and cephalosporins. The clavulanate potassium molecular formula is C8H8KNO5, and the molecular weight is 237.25. Chemically, clavulanate potassium is potassium (Z)-(2R ,5R)-3-(2- hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]-heptane-2-carboxylate and may be represented structurally as: Inactive Ingredients: Powder for Oral Suspension- Colloidal silicon dioxide, strawberry cream flavor, xanthan gum, aspartamea, sodium carboxymethylcellulose, and silicon dioxide. a See PRECAUTIONS—Information for the Patient/Phenylketonurics. Each 5 mL of reconstituted 600 mg/42.9 mg per 5 mL oral suspension of AUGMENTIN ES-600 contains 0.23 mEq potassium. CLINICAL PHARMACOLOGY The pharmacokinetics of amoxicillin and clavulanate were determined in a study of 19 pediatric patients, 8 months to 11 years, given AUGMENTIN ES-600 Powder for Oral Suspension at an amoxicillin dose of 45 mg/kg q12h with a snack or meal. The mean plasma amoxicillin and clavulanate pharmacokinetic parameter values are listed in the following table. Table 1. Mean (±SD) Plasma Amoxicillin and Clavulanate Pharmacokinetic Parameter Values Following Administration of 45 mg/kg of AUGMENTIN ES-600 Powder for Oral Suspension Every 12 Hours to Pediatric Patients PARAMETER* AMOXICILLIN CLAVULANATE Cmax (mcg/mL) 15.7 ± 7.7 1.7 ± 0.9 Tmax (hr) 2.0 (1.0 - 4.0) 1.1 (1.0 - 4.0) AUC 0-t 59.8 ± 20.0 4.0 ± 1.9 (mcghr/mL) T1/2 (hr) 1.4 ± 0.3 1.1 ± 0.3 CL/F (L/hr/kg) 0.9 ± 0.4 1.1 ± 1.1 * Arithmetic mean ± standard deviation, except Tmax values which are medians (ranges). The effect of food on the oral absorption of AUGMENTIN ES-600 Powder for Oral Suspension has not been studied. Approximately 50% to 70% of the amoxicillin and approximately 25% to 40% of the clavulanic acid are excreted unchanged in urine during the first 6 hours after administration of 10 mL of 250 mg/5 mL suspension of AUGMENTIN. Concurrent administration of probenecid delays amoxicillin excretion but does not delay renal excretion of clavulanic acid. Neither component in AUGMENTIN ES-600 Powder for Oral Suspension is highly protein-bound; clavulanic acid has been found to be approximately 25% bound to human serum and amoxicillin approximately 18% bound. Oral administration of a single dose of AUGMENTIN ES-600 Powder for Oral Suspension at 45 mg/kg (based on the amoxicillin component) to pediatric patients, 9 months to 8 years, yielded the following pharmacokinetic data for amoxicillin in plasma and middle ear fluid (MEF). Table 2. Amoxicillin Concentrations in Plasma and Middle Ear Fluid Following Administration of 45 mg/kg of AUGMENTIN ES-600 Powder for Oral Suspension to Pediatric Patients Amoxicillin Amoxicillin concentration in concentration in MEF Timepoint plasma (mcg/mL) (mcg/mL) 7.7 3.2 mean 9.3 3.5 1 hour median 1.5 - 14.0 0.2 - 5.5 range (n = 5) (n = 4) 15.7 3.3 mean 13.0 2.4 2 hour median 11.0 - 25.0 1.9 - 6 range range ( n= 7) (n = 5) 13.0 5.8 mean 12.0 6.5 3 hour median 5.5 - 21.0 3.9 - 7.4 range (n = 5) (n = 5) Dose administered immediately prior to eating. Amoxicillin diffuses readily into most body tissues and fluids with the exception of the brain and spinal fluid. The results of experiments involving the administration of clavulanic acid to animals suggest that this compound, like amoxicillin, is well distributed in body tissues. Microbiology: Amoxicillin is a semisynthetic antibiotic with a broad spectrum of bactericidal activity against many gram-positive and gram-negative microorganisms. Amoxicillin is, however, susceptible to degradation by β-lactamases, and therefore, its spectrum of activity does not include organisms which produce these enzymes. Clavulanic acid is a β-lactam, structurally related to penicillin, which possesses the ability to inactivate a wide range of β-lactamase enzymes commonly found in microorganisms resistant to penicillins and cephalosporins. In particular, it has good activity against the clinically important plasmid-mediated β-lactamases frequently found responsible for transferred drug resistance. The clavulanic acid component of AUGMENTIN ES-600 Powder for Oral Suspension protects amoxicillin from degradation by β-lactamase enzymes and effectively extends the antibiotic spectrum of amoxicillin to include many bacteria normally resistant to amoxicillin and other β-lactam antibiotics. Thus, AUGMENTIN ES-600 Powder for Oral Suspension possesses the distinctive properties of a broad-spectrum antibiotic and a β-lactamase inhibitor. Amoxicillin/clavulanic acid has been shown to be active against most isolates of the following microorganisms, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section. Aerobic Gram-Positive Microorganisms: Streptococcus pneumoniae (including isolates with penicillin MICs ≤ 2 mcg/mL) Aerobic Gram-Negative Microorganisms: Haemophilus influenzae (including β-lactamase–producing isolates) Moraxella catarrhalis (including β-lactamase–producing isolates) The following in vitro data are available, but their clinical significance is unknown. At least 90% of the following microorganisms exhibit in vitro minimum inhibitory concentrations (MICs) less than or equal to the susceptible breakpoint for amoxicillin/clavulanic acid. However, the safety and efficacy of amoxicillin/clavulanic acid in treating infections due to these microorganisms have not been established in adequate and well-controlled trials. Aerobic Gram-Positive Microorganisms: Staphylococcus aureus (including β-lactamase–producing isolates) NOTE: Staphylococci which are resistant to methicillin/oxacillin must be considered resistant to amoxicillin/clavulanic acid. Streptococcus pyogenes NOTE: S. pyogenes do not produce β-lactamase, and therefore, are susceptible to amoxicillin alone. Adequate and well-controlled clinical trials have established the effectiveness of amoxicillin alone in treating certain clinical infections due to S. pyogenes. Susceptibility Test Methods: When available, the clinical microbiology laboratory should provide cumulative results of in vitro susceptibility test results for antimicrobial drugs used in local hospitals and practice areas to the physician as periodic reports that describe the susceptibility profile of nosocomial and community- acquired pathogens. These reports should aid the physician in selecting the most effective antimicrobial. Dilution Technique: Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure.1,2 Standardized procedures are based on dilution methods (broth for S. pneumoniae and H. influenzae) or equivalent with standardized inoculum concentration and standardized concentrations of amoxicillin/clavulanate potassium powder. The recommended dilution pattern utilizes a constant amoxicillin/clavulanate potassium ratio of 2 to 1 in all tubes with varying amounts of amoxicillin. MICs are expressed in terms of the amoxicillin concentration in the presence of clavulanic acid at a constant 2 parts amoxicillin to 1 part clavulanic acid. The MIC values should be interpreted according to criteria provided in Table 3. Diffusion Technique: Quantitative methods that require measurement of zone diameters also provides reproducible estimates of the susceptibility of bacteria to antimicrobials. One such standardized technique requires the use of a standardized inoculum concentration.2,3 This procedure uses paper disks impregnated with 30 mcg amoxicillin/clavulanate potassium (20 mcg amoxicillin plus 10 mcg clavulanate potassium) to test susceptibility of microorganisms to amoxicillin/clavulanate potassium. Disk diffusion zone sizes should be interpreted according to criteria provided in Table 3. Table 3. Susceptibility Test Result Interpretive Criteria for Amoxicillin/Clavulanate Potassium Minimum Inhibitory Concentration Disk Diffusion
Load more

Recommended publications
  • AP Suspension and Powder
    AP Suspension and Powder • Easily application and distribution • Ultrafine surface • Excellent stability Struers AP Suspensions and Powders are based on ultra pure aluminium oxides (alumina). They are available in two forms, Struers ApS deagglomerated and agglomerated. Pederstrupvej 84 DK-2750 Ballerup, Denmark Phone +45 44 600 800 Fax +45 44 600 801 [email protected] www.struers.com AUSTRALIAN & NEW ZEALAND NETHERLANDS Struers Australia Struers GmbH Nederland 27 Mayneview Street Zomerdijk 34 A Milton QLD 4064 3143 CT Maassluis Australia Telefoon +31 (10) 599 7209 Phone +61 7 3512 9600 Fax +31 (10) 5997201 Fax +61 7 3369 8200 [email protected] [email protected] NORWAY BELGIUM (Wallonie) Struers ApS, Norge Deagglomerated Agglomerated Struers S.A.S. Sjøskogenveien 44C 370, rue du Marché Rollay 1407 Vinterbro F- 94507 Champigny Telefon +47 970 94 285 Deagglomerated sur Marne Cedex [email protected] Téléphone +33 1 5509 1430 AP-D, deagglomerated aluminas are premium polishing abrasive and are agglomerate-free. The uniform Télécopie +33 1 5509 1449 AUSTRIA [email protected] Struers GmbH crystals ensure an ultrafine surface. Zweigniederlassung BELGIUM (Flanders) Österreich Struers GmbH Nederland Betriebsgebiet Puch Nord 8 Agglomerated Zomerdijk 34 A 5412 Puch 3143 CT Maassluis Telefon +43 6245 70567 AP-A, agglomerated aluminas are easily broken down during the polishing process while still providing Telefoon +31 (10) 599 7209 Fax +43 6245 70567-78 Fax +31 (10) 5997201 [email protected] faster initial stock removal. [email protected] POLAND CANADA Struers Sp. z o.o. Alumina powders Struers Ltd. Oddział w Polsce 7275 West Credit Avenue ul. Jasnogórska 44 Alumina powders consist of uniform particles with a narrow particle size distribution.
    [Show full text]
  • Grade 6 Science Mechanical Mixtures Suspensions
    Grade 6 Science Week of November 16 – November 20 Heterogeneous Mixtures Mechanical Mixtures Mechanical mixtures have two or more particle types that are not mixed evenly and can be seen as different kinds of matter in the mixture. Obvious examples of mechanical mixtures are chocolate chip cookies, granola and pepperoni pizza. Less obvious examples might be beach sand (various minerals, shells, bacteria, plankton, seaweed and much more) or concrete (sand gravel, cement, water). Mechanical mixtures are all around you all the time. Can you identify any more right now? Suspensions Suspensions are mixtures that have solid or liquid particles scattered around in a liquid or gas. Common examples of suspensions are raw milk, salad dressing, fresh squeezed orange juice and muddy water. If left undisturbed the solids or liquids that are in the suspension may settle out and form layers. You may have seen this layering in salad dressing that you need to shake up before using them. After a rain fall the more dense particles in a mud puddle may settle to the bottom. Milk that is fresh from the cow will naturally separate with the cream rising to the top. Homogenization breaks up the fat molecules of the cream into particles small enough to stay suspended and this stable mixture is now a colloid. We will look at colloids next. Solution, Suspension, and Colloid: https://youtu.be/XEAiLm2zuvc Colloids Colloids: https://youtu.be/MPortFIqgbo Colloids are two phase mixtures. Having two phases means colloids have particles of a solid, liquid or gas dispersed in a continuous phase of another solid, liquid, or gas.
    [Show full text]
  • New Zealand Regulatory Guidelines for Medicines
    New Zealand Regulatory Guidelines for Medicines Part G: Resources Edition 6.13 March 2011 (consolidation of fifth edition and subsequent updates) Table of Contents PART G: RESOURCES Section 1: Description of Dosage Form...............................................................................2 Section 2: Routes of Administration....................................................................................4 Section 3: Shelf Life and Storage Conditions .....................................................................5 Section 4: Abbreviations.......................................................................................................6 Description of Dosage Form The dosage form description for a product should be selected from the following list: Block Granules, oral Capsule Implant, subcutaneous Capsule, combination Implant, intracranial Capsule, liquid filled Implant, intraocular Capsule, modified release Infusion, concentrate Capsule, powder filled Infusion, emulsion Capsule, powder filled, nasal inhalation Infusion, powder for Capsule, soft gelatin Infusion, powder for concentrate Cement, bone, liquid component Infusion, solution Cement, bone, powder component Inhalation, capsule, liquid filled Cement, dental Inhalation, capsule, powder filled Chewing gum Inhalation, powder Chocolate, medicated Inhalation, solution Combination Inhalation, solution, powder for Condom, medicated Inhalation, suspension Condom with spermicide Inhalation, volatile liquid Cream, rectal Inhaler, aerosol, metered Cream, topical Injection
    [Show full text]
  • 1 090304 Quiz 8 Introduction to Polymers (Chemistry) This Week We
    090304 Quiz 8 Introduction to Polymers (Chemistry) This week we ran a suspension polymerization to make polystyrene, a solution polymerization to make polyacrylamide and we discussed Ziegler-Natta polymerization to make polypropylene. 1) Suspension polymerization is similar to emulsion polymerization. a) Describe the importance of water to emulsion and suspension polymerization. Does water play an identical role in these two polymerizations? Is water a solvent? b) Describe the initiator that we used in suspension polymerization. What condition is needed to initiate this reaction? Why was a different initiator used in the emulsion polymerization? c) What is divinyl benzene and why is it included in this reaction? d) What controls the size of the polymer beads (droplet size) that result from suspension polymerization? e) What was the advantage of emulsion polymerization (over suspension polymerization) that lead to its development by Goodyear Tire and Rubber in the 1920’s? 2) Polyacrylamide is soluble in water as is the monomer acrylamide therefore this is a solution polymerization. a) Use the words ferric and ferrous to describe the initiator system for this polymerization. Why is this called a redox system? b) When hydrogen peroxide was added to the reaction mixture it turned from a faint bluish green to red (rust color). Later the color seemed to fade. Why did it change color? c) What temperature was needed to perform this polymerization? Why? d) How was polymer separated from the viscous reaction mixture after polymerization? e) Explain the disadvantage of solution polymerization compared to emulsion or suspension polymerization. 3) We looked at Ziegler-Natta polymerization briefly.
    [Show full text]
  • Instruction Booklet ATTENTION: There Are 3 Critical Steps in the Reconstitution of Sandostatin® LAR
    Instruction Booklet ATTENTION: There are 3 critical steps in the reconstitution of Sandostatin® LAR. Not following them could result in failure to deliver the Preparation and Administration of drug appropriately. • The injection kit must reach room temperature. Remove the injection kit from the fridge and let the kit stand at room temperature for a minimum of 30 minutes before reconstitution, but do not exceed 24 hours. • After adding the diluent solution, ensure that the powder is fully saturated by letting the vial stand for a minimum FOR DEEP INTRAGLUTEAL INJECTION ONLY of 2 minutes and up to 5 minutes. Read this entire booklet before proceeding. • After saturation, shake the vial moderately in a If you have questions about preparation and/or administration horizontal direction for a minimum of 30 seconds, until of Sandostatin® LAR Depot, please call 1-888-NOW-NOVA uniform suspension is formed. (1-888-669-6682). Instructions for gluteal Intramuscular (IM) Injection of Step 1 Sandostatin® LAR Depot (octreotide acetate) for injectable suspension • Remove the Sandostatin® LAR injection kit from Important Information for Health Care Professionals refrigerated storage. Successful preparation and administration ATTENTION: It is essential to start of Sandostatin® LAR Depot relies on proper the reconstitution process only after suspension technique. the injection kit has reached room Follow each of the steps outlined in this instruction booklet temperature. Let the kit stand to ensure complete saturation of the powder and its uniform at room temperature for a minimum suspension prior to deep intragluteal injection. of 30 minutes before reconstitution, but do not exceed 24 hours. It is critical that Sandostatin® LAR Depot and the diluent be allowed to reach room temperature and then be mixed Note: The injection kit can be re-refrigerated if needed.
    [Show full text]
  • INVEGA SUSTENNA® (Paliperidone Palmitate)
    INVEGA SUSTENNA® INVEGA SUSTENNA® (paliperidone palmitate) extended-release injectable suspension, for intramuscular use (paliperidone palmitate) extended-release injectable suspension, for intramuscular use --------------------------- DOSAGE FORMS AND STRENGTHS --------------------------- HIGHLIGHTS OF PRESCRIBING INFORMATION Extended-release injectable suspension: 39 mg/0.25 mL, 78 mg/0.5 mL, 117 mg/0.75 mL, These highlights do not include all the information needed to use 156 mg/mL, or 234 mg/1.5 mL (3) INVEGA SUSTENNA® safely and effectively. See full prescribing information for INVEGA SUSTENNA®. ----------------------------------- CONTRAINDICATIONS ----------------------------------- INVEGA SUSTENNA® (paliperidone palmitate) extended-release injectable Known hypersensitivity to paliperidone, risperidone, or to any excipients in suspension, for intramuscular use INVEGA SUSTENNA®. (4) Initial U.S. Approval: 2006 -----------------------------WARNINGS AND PRECAUTIONS ----------------------------- WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS • Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with WITH DEMENTIA-RELATED PSYCHOSIS Dementia-Related Psychosis: Increased incidence of cerebrovascular adverse See full prescribing information for complete boxed warning. reactions (e.g. stroke, transient ischemic attack). (5.2) • Neuroleptic Malignant Syndrome: Manage with immediate discontinuation of Elderly patients with dementia-related psychosis treated with antipsychotic drug and close monitoring. (5.3) drugs are
    [Show full text]
  • Chapter 18 Solutions and Their Behavior
    Chapter 18 Solutions and Their Behavior 18.1 Properties of Solutions Lesson Objectives The student will: • define a solution. • describe the composition of solutions. • define the terms solute and solvent. • identify the solute and solvent in a solution. • describe the different types of solutions and give examples of each type. • define colloids and suspensions. • explain the differences among solutions, colloids, and suspensions. • list some common examples of colloids. Vocabulary • colloid • solute • solution • solvent • suspension • Tyndall effect Introduction In this chapter, we begin our study of solution chemistry. We all might think that we know what a solution is, listing a drink like tea or soda as an example of a solution. What you might not have realized, however, is that the air or alloys such as brass are all classified as solutions. Why are these classified as solutions? Why wouldn’t milk be classified as a true solution? To answer these questions, we have to learn some specific properties of solutions. Let’s begin with the definition of a solution and look at some of the different types of solutions. www.ck12.org 394 E-Book Page 402 Homogeneous Mixtures A solution is a homogeneous mixture of substances (the prefix “homo-” means “same”), meaning that the properties are the same throughout the solution. Take, for example, the vinegar that is used in cooking. Vinegar is approximately 5% acetic acid in water. This means that every teaspoon of vinegar contains 5% acetic acid and 95% water. When a solution is said to have uniform properties, the definition is referring to properties at the particle level.
    [Show full text]
  • Ways to Physically Separate a Mixture There Are 2 Types of Mixtures
    Mixtures 12 Mixtures Homogenous Compare Heterogeneous compounds and Suspension Mixtures. Colloid Solution Differentiate Solute/Solvent between solutions, suspensions, and colloids Comparing Mixtures and Compounds Mixtures Compounds Made of 2 or more substances Made of 2 or more substances physically combined chemically combined Substances keep their own properties Substances lose their own properties Can be separated by physical means Can be separated only by chemical means Have no definite chemical composition Have a definite chemical composition What method is used to separate mixtures Ways to physically separate a Mixture based on boiling • Distillation – uses boiling point point? • Magnet – uses magnetism What method is used • Centrifuge – uses density to separate mixtures based on density? • Filtering – separates large particles from smaller ones What method is used There are 2 types of mixtures: to separate mixtures (1) Heterogeneous Mixtures: the parts mixed together can still be based on particle size? distinguished from one another...NOT uniform in composition Give examples of a heterogeneous Examples: chicken soup, fruit salad, dirt, sand in water mixture Mixtures 12 (2) Homogenous Mixtures: the parts mixed together cannot be distinguished from one another...completely uniform in composition. Give examples of a homogenous Examples: Air, Kool-aid, Brass, salt water, milk mixture Differentiate Types of Homogenous mixtures between a homogenous 1. Suspensions mixture and a i.e. chocolate milk, muddy water, Italian dressing heterogeneous mixture. They are cloudy (usually a liquid mixed with small solid particles) Identify an example of a suspension. Needs to be shaken or stirred to keep the solids from Will the solid settling particles settle in a suspension? The solids can be filtered out 2.
    [Show full text]
  • Biphasic Dosage Forms Suspensions and Emulsions Unit 7
    BIPHASIC DOSAGE FORMS SUSPENSIONS AND EMULSIONS UNIT 7 Dr.N Damodharan Professor and Head Department of Pharmaceutics SRM College of Pharmacy Suspensions Heterogenous biphasic dosage form -- solid is dispersed in liquid medium. Dispersed phase, dispersion medium PROPERTIES: --Rapid settling ---Easily redisperdible,pourable ---if parenteral—flow through syringe needle ---if external---spread easily ---Pleasing in colour , odour, appearance. Types: ---Deflocculated ---Flocculated PROPERTIES: ---Interfacial property ---Electrical property zDispersions containing coarse particles, usually 10 to 50 um in size, are referred to as coarse dispersion. zDispersions containing particles of smaller size are termed fine dispersions (0.5 to 10 um) Suspensions In general sense, Suspension may include: ¾ Gels ¾ Lotions ¾ Magmas and Milk ¾ Mixtures Reasons for Suspensions ¾ Certain drugs are chemically unstable when in solution but stable when suspended. ¾ Suspension insures chemical stability while permitting liquid therapy. ¾ Many patients prefer liquid form than solid forms for swallowing. ¾ Convenience in administration ¾ Safety and convenience of liquid doses for infants and children. ¾ Disagreeable taste of certain drugs when given in solution is negligible when the drug is administered as undissolved particles of a suspension, e.g chloramphenicol Features Desired in a Pharmaceutical Suspensions 1. A properly prepared suspension should settle slowly and should be readily re- dispersed upon gentle shaking of the container. 2. The characteristics of the suspension should be such that the particles size of the suspensoid remains fairly constant throughout long periods of undisturbed standing. 3. The suspension should pour readily and evenly from its container Physical Features of the Dispersed Phase of a Suspension Good pharmaceutical suspensions, the particle diameter is between 1 to 50.
    [Show full text]
  • Thin Films As an Emerging Platform for Drug Delivery
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector asian journal of pharmaceutical sciences 11 (2016) 559–574 HOSTED BY Available online at www.sciencedirect.com ScienceDirect journal homepage: www.elsevier.com/locate/ajps Review Thin films as an emerging platform for drug delivery Sandeep Karki a,1, Hyeongmin Kim a,b,c,1, Seon-Jeong Na a, Dohyun Shin a,c, Kanghee Jo a,c, Jaehwi Lee a,b,c,* a Pharmaceutical Formulation Design Laboratory, College of Pharmacy, Chung-Ang University, Seoul 06974, Republic of Korea b Bio-Integration Research Center for Nutra-Pharmaceutical Epigenetics, Chung-Ang University, Seoul 06974, Republic of Korea c Center for Metareceptome Research, Chung-Ang University, Seoul 06974, Republic of Korea ARTICLE INFO ABSTRACT Article history: Pharmaceutical scientists throughout the world are trying to explore thin films as a novel Received 21 April 2016 drug delivery tool. Thin films have been identified as an alternative approach to conven- Accepted 12 May 2016 tional dosage forms. The thin films are considered to be convenient to swallow, self- Available online 6 June 2016 administrable, and fast dissolving dosage form, all of which make it as a versatile platform for drug delivery. This delivery system has been used for both systemic and local action via Keywords: several routes such as oral, buccal, sublingual, ocular, and transdermal routes. The design Thin film of efficient thin films requires a comprehensive knowledge of the pharmacological and phar- Film-forming polymer maceutical properties of drugs and polymers along with an appropriate selection of Mechanical properties manufacturing processes.
    [Show full text]
  • PFIZER Package Leaflet: Information for the Patient Depo-Provera® 150 Mg/Ml Sterile Suspension for Injection Medroxyprogesterone Acetate
    PFIZER Package leaflet: Information for the patient Depo-Provera® 150 mg/ml Sterile Suspension for Injection Medroxyprogesterone acetate Please read all of this leaflet carefully before you start using this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor, pharmacist or nurse. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any of the side effects, talk to your doctor, nurse or healthcare provider. This includes any possible side effects not listed in this leaflet. See section 4. IMPORTANT INFORMATION YOU SHOULD KNOW ABOUT DEPO-PROVERA Depo-Provera is a very effective injectable contraceptive which gives 12 weeks continuous contraception with each injection. The effect is not reversible once the injection is given. • You must have injections of this contraceptive regularly every 12 weeks; otherwise you may risk becoming pregnant (see section 3). • Depo-Provera may not be suitable for every woman. You will need to discuss with your doctor or healthcare professional providing your contraception on whether it is suitable for you, especially if you wish to use it for more than 2 years (See section 1). • Depo-Provera may not be suitable for you if you have a history of certain medical conditions (see section 2) or if you are taking a medicine called aminoglutethiamide that thins the blood (see section 2). Your doctor or nurse should take a full medical history before prescribing Depo-Provera.
    [Show full text]
  • Nanosuspension Loaded Oral Films: a Breakthrough Approach
    Anu Mathew et al /J. Pharm. Sci. & Res. Vol. 12(8), 2020, 1012-1017 Nanosuspension Loaded Oral Films: A Breakthrough Approach Anu Mathew*, Susan Jacob, Shyma M.S Department of Pharmaceutics, Mar Dioscorus College of Pharmacy, Alathara, Sreekaryam, Thiruvanathapuram, Kerala, India Abstract Nanotechnology-based techniques are widely used in pharmaceuticals for improving the solubility of poorly water-soluble drugs. The oral film containing nanoparticles was developed with the aim to transform nanosuspensions into solid dosage form and thereby increasing oral bioavailability of drugs. Nanosuspensions can be prepared by various methods such as high shear homogenization, solvent evaporation, and then lyophilized to get nanoparticles. These nanoparticles get incorporated in the oral film by mixing it with HPMC E15 or HPMC E5 and PEG 400 by the process of solvent casting. Key words: Homogenization, nanosuspension, oral films, solvent casting INTRODUCTION formulation approach is most suitable for the compound Oral administration is the most preferred route due to its with high log P value, high melting point, and high dose several advantages such as patient compliance, ease of and for the drugs that are insoluble both in water and in administration, pain reduction, to accommodate various organic media. [2] drug candidates. Geriatric & pediatric patients have problems in swallowing of oral solid dosage forms such as Advantages 1] tablets & capsules. In these cases, fast dissolving drug Provides ease of manufacture and scale-up for large- delivery is a promising approach to increase patient scale production. compliance. These oral films undergo rapid disintegration Long-term physical stability due to the presence of and can be self- administered without swallowing and stabilizers.
    [Show full text]